4.7 Article

AD risk score for the early phases of disease based on unsupervised machine learning

期刊

ALZHEIMERS & DEMENTIA
卷 16, 期 11, 页码 1524-1533

出版社

WILEY
DOI: 10.1002/alz.12140

关键词

Alzheimer's disease; cognitive testing; latent variable; machine learning; multidomain biomarkers; progression; risk score; unsupervised learning

资金

  1. pilot project grant from the Johns Hopkins Alzheimer's Disease Research Center [P50-AG00146]
  2. NIA [K01-AG050699]
  3. National Institute on Aging [U19-AG033655]
  4. Alzheimer's Disease Neuroimaging Initiative (ADNI
  5. National Institutes of Health) [U01-AG024904]
  6. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  7. National Institute on Aging
  8. National Institute of Biomedical Imaging and Bioengineering
  9. AbbVie
  10. Alzheimer's Association
  11. Alzheimer's Drug Discovery Foundation
  12. Araclon Biotech
  13. BioClinica, Inc.
  14. Biogen
  15. Bristol-Myers Squibb Company
  16. CereSpir, Inc.
  17. Cogstate
  18. Eisai Inc.
  19. Elan Pharmaceuticals, Inc.
  20. Eli Lilly and Company
  21. EuroImmun
  22. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  23. Fujirebio
  24. GE Healthcare
  25. IXICO Ltd.
  26. Janssen Alzheimer Immunotherapy Research & Development, LLC
  27. Johnson & Johnson Pharmaceutical Research & Development LLC
  28. Lumosity
  29. Lundbeck
  30. Merck Co., Inc.
  31. Meso Scale Diagnostics, LLC
  32. NeuroRx Research
  33. Neurotrack Technologies
  34. Novartis Pharmaceuticals Corporation
  35. Pfizer Inc.
  36. Piramal Imaging
  37. Servier
  38. Takeda Pharmaceutical Company
  39. Transition Therapeutics
  40. Canadian Institutes of Health Research

向作者/读者索取更多资源

Introduction: Identifying cognitively normal individuals at high risk for progression to symptomatic Alzheimer's disease (AD) is critical for early intervention. Methods: An AD risk score was derived using unsupervised machine learning. The score was developed using data from 226 cognitively normal individuals and included cerebrospinal fluid, magnetic resonance imaging, and cognitive measures, and validated in an independent cohort. Results: Higher baseline AD progression risk scores (hazard ratio = 2.70, P < 0.001) were associated with greater risks of progression to clinical symptoms of mild cognitive impairment (MCI). Baseline scores had an area under the curve of 0.83 (95% confidence interval: 0.75 to 0.91) for identifying subjects who progressed to MCI/dementia within 5 years. The validation procedure, using data from the Alzheimer's Disease Neuroimaging Initiative, demonstrated accuracy of prediction across the AD spectrum. Discussion: The derived risk score provides high predictive accuracy for identifying which individuals with normal cognition are likely to show clinical decline due to AD within 5 years.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据